Key result
P2X4 receptor overexpression slows HF progression and reverses myocyte dysfunction in cardiomyopathic mice.
Why the study?
Does binary cardiac transgenic overexpression of P2X4 receptors improve cardiac myocyte dysfunction in cardiomyopathic calsequestrin mice?
Does binary cardiac transgenic overexpression of P2X4 receptors improve cardiac myocyte dysfunction in cardiomyopathic calsequestrin mice?
Overexpression of P2X4 receptors delays heart failure progression and reverses cardiac myocyte dysfunction in a mouse model of cardiomyopathy.
P2X4 overexpression may attenuate murine cardiomyopathy; hypothesis-generating and leaves open human therapeutic translation.
Binary cardiac transgenic (Tg) overexpression of P2X(4) receptors (P2X(4)R) improved the survival of the cardiomyopathic calsequestrin (CSQ) mice. Here we studied the mechanism of rescue using binary P2X(4)R/CSQ Tg and CSQ Tg mice as models. Cellular and intact heart properties were determined by simultaneous sarcomere shortening (SS) and Ca(2+) transients in vitro and echocardiography in vivo. Similar to a delay in death, binary mice exhibited a slowed heart failure progression with a greater left ventricular (LV) fractional shortening (FS) and thickness and a concomitant lesser degree of LV dilatation in both systole and diastole at 8 or 12 wk. By 16 wk, binary hearts showed similarly depressed FS and thinned out LV and equal enlargement of LV as did 12-wk-old CSQ hearts. Binary cardiac myocytes showed higher peak basal cell shortening (CS) and SS as well as greater basal rates of shortening and relaxation than did the CSQ myocytes at either 8 or 12 wk. Similar data were obtained in comparing the Ca(2+) transient. At 16 wk, binary myocytes were like the 12-wk-old CSQ myocytes with equally depressed CS, SS, and Ca(2+) transient. CSQ myocytes were longer than myocytes from wild-type and binary mice at 12 wk of age. At 16 wk, the binary myocyte length increased to that of the 12-wk-old CSQ myocyte, parallel to LV dilatation. The data suggest a unique mechanism, which involves a reversal of cardiac myocyte dysfunction and a delay in heart failure progression. It represents an example of targeting the abnormal failing myocyte in treating heart failure.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2009) studied Cardiomyopathy. Transgenic overexpression of P2X4 receptors vs. CSQ Tg mice was evaluated on Heart failure progression (LV fractional shortening, thickness, dilatation, and cellular properties). Transgenic overexpression of P2X4 receptors in cardiomyopathic mice slowed heart failure progression and reversed cardiac myocyte dysfunction at 8 and 12 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: